Monte Rosa Therapeutics, Inc.
GLUE
Rank in Stocks
#9138
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to... Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Share Price
$10.58
Last synced: 2026-11-09
Market Cap
$902.62M
Change (1 day)
0.09%
Change (1 year)
-26.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Monte Rosa Therapeutics, Inc. (GLUE)
Category
Healthcare
Operating Margin for Monte Rosa Therapeutics, Inc. (GLUE)
Operating Margin as of November 2026 TTM: -633.04%
According to Monte Rosa Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -633.04%. At the end of 2025 the company had an operating margin of -43.83%.
Operating Margin history for Monte Rosa Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -633.04% | 1,344.31% |
| 2025 | -43.83% | -59.14% |
| 2024 | -107.26% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.76% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Monte Rosa Therapeutics, Inc.'s operating margin
What is Monte Rosa Therapeutics, Inc.'s operating margin?
Monte Rosa Therapeutics, Inc.'s operating margin is -633.04%, as of Nov 2026.
What was Monte Rosa Therapeutics, Inc.'s operating margin in 2025?
In 2025, Monte Rosa Therapeutics, Inc.'s operating margin was -43.83%, compared with -107.26% in 2024.
How has Monte Rosa Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Monte Rosa Therapeutics, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-107.26%).
How does Monte Rosa Therapeutics, Inc.'s operating margin compare with similar companies?
Monte Rosa Therapeutics, Inc.'s operating margin (-633.04%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.